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Abstract
The proteolipid protein (Plp) gene promoter is responsible for driving expression of one of the major components of myelin
– PLP and its splice variant DM-20. Both products are classically thought to express predominantly in oligodendrocytes.
However, accumulating evidence suggests Plp expression is more widespread than previously thought. In an attempt to
create a mouse model for inducing oligodendrocyte-specific gene deletions, we have generated transgenic mice expressing
a Cre recombinase cDNA under control of the mouse Plp promoter. We demonstrate Plp promoter driven Cre expression is
restricted predominantly to mature oligodendrocytes of the central nervous system (CNS) at postnatal day 28. However,
crosses into the Rosa26
LacZ and mT/mG reporter mouse lines reveal robust and widespread Cre activity in neuronal tissues at
E15.5 and E10.5 that is not strictly oligodendrocyte lineage specific. By P28, all CNS tissues examined displayed high levels of
reporter gene expression well outside of defined white matter zones. Importantly, our study reinforces the emerging idea
that Plp promoter activity is not restricted to the myelinating cell lineage, but rather, has widespread activity both during
embryonic and early postnatal development in the CNS. Specificity of the promoter to the oligodendrocyte cell lineage, as
shown through the use of a tamoxifen inducible Plp-CreER
t line, occurs only at later postnatal stages. Understanding the
temporal shift in Plp driven expression is of consequence when designing experimental models to study oligodendrocyte
biology.
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Introduction
Proteolipid protein (PLP), a tetraspan membrane protein, is the
most abundant component of CNS myelin. It is encoded by a highly
conserved 17 Kb gene (Plp) containing seven exons. By means of an
alternate splicing event, a second protein, DM-20, is also generated.
Plp, though active at low levels during embryonic development, is
expressed maximally in mature myelinating cells, while DM-20 is
expressed earlier during embryonic development in both neural, and
subsequently, oligodendrocyte progenitors [1,2,3]. Together, PLP
and DM-20 play an important role in regulating proper oligoden-
drocyte maturation and myelin compaction/stability over time [4,5].
The Plp promoter and its regulatory elements, located in exon 1
and intron 1 of the gene, were previously shown to dictate
expression specifically to oligodendrocytes [6,7,8] and Schwann
cells [9,10] at various stages of development. Although the
promoter is generally considered oligodendrocyte lineage specific,
accumulating evidence suggests a Plp expression pattern outside of
defined white matter zones; included are both glial and neuronal
CNS subpopulations, implying a role for Plp in activities
independent of myelination [11,12,13,14,15,16].
To study Plp promoter driven expression patterns across time in
CNS tissues, we have generated and characterized transgenic mice
expressing full length Cre cDNA under control of the mouse Plp
promoter (Plp-Cre). We did not necessarily expect the transgene to
completely faithfully mimic the endogenous Plp gene expression
due to the phenomenon of position-effect in transgenic mice, but
rather we wished to test whether such cassettes can provide cell
specificity in a temporal fashion. These mice demonstrate a
transient spatio-temporal expression pattern for Plp-Cre.A s
expected, at P28 the Plp promoter drove Cre expression
predominantly in mature oligodendrocytes; however, by crossing
the Plp-Cre line to either the Rosa26
LacZ [17] or the mT/mG [18]
reporter mice, a more promiscuous expression pattern was
observed during embryonic and early postnatal stages of
development. Specificity of the promoter to the oligodendrocyte
cell lineage, as shown through the use of a tamoxifen inducible Plp-
CreER
t line [19], occurs only at later postnatal stages.
Our work reinforces previous studies supporting a role for the
Plp promoter in the nervous system outside of myelinating cell
lineages, particularly early in development. Consequently, the
promoter construct should be used with caution in studies
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19772requiring genetic modifications strictly in myelinating cells,




The mice were cared for according to the Canadian Council on
Animal Care (CCAC) guidelines. Ethical approval for experiments
conducted was obtained from the University of Ottawa Animal
Care Committee under protocol approval OGH-118 and OGH-
119.
Transgenic and Reporter Mice
The Cre cDNA (kindly provided by Dr. Robin Parks, Ottawa
Hospital Research Institute) was inserted into the Plp promoter
cassette, consisting of exon 1 and intron 1 of the mouse Plp gene
[7]. The resulting transgene construct was microinjected into one-
cell mouse embryos. Tail biopsies were obtained from potential
founder mice, DNA was extracted and transgenic mice were
identified by PCR amplification using sense oligo 59 TGG GTG
TTG GTT TTT GGA GA 39 (specific to the Plp promoter) and
antisense oligo 59 CGC ATA ACC AGT GAA ACA GCA 39
(specific to the Cre cDNA). Positive founder mice were bred with
C57BL/6 mice (obtained from Charles River) to establish two
independent transgenic lines. Plp-CreER
t mice were kindly
provided by Dr. Brian Popko [19]. One mg of tamoxifen (20 mL
of a 50 mg/ml solution) was administered intraperitoneal once a
day for 5 consecutive days to P16 mice. A single 1 mg injection
was given to P4 mice. Cre protein distribution was assessed by
crossing transgenic mice into the Rosa26
LacZ reporter line [17] or to
a floxed stop tdTomato-EGFP (mT/mG) fluorescent reporter
mouse line [18]. Animals homozygous for the Rosa26
LacZ or mT/
mG locus were crossed to mice heterozygous for the Cre transgene,
generating a final line of mice heterozygous for both the Cre and
respective reporter transgenes. The genotype of offspring mice was
confirmed by PCR.
RT-PCR Analysis
For reverse transcription-polymerase chain reaction (RT-PCR)
analysis, RNA was isolated from transgenic P4 and P28 tissues
from the two Plp-Cre founder lines. To produce cDNA, equal
amounts of RNA were reverse-transcribed in a standard reaction
with MuLV reverse transcriptase (Invitrogen). PCR amplification
using the sense oligo 59 CCT TCC AGC TGA GCA AAG TC 39
(specific to Plp exon 1), and the antisense oligo 59 CGC ATA ACC
AGT GAA ACA GCA 39 (specific to the Cre cDNA) yielded a 440
nucleotide fragment. Primers were chosen to flank the intronic
region of the construct to selectively amplify the RNA transcript
and prevent amplifying any contaminating genomic DNA. The
reaction began with a 3 min incubation time at 94uC followed by
30 cycles of 45 sec at 94uC, 45 sec at 55uC, 1 min at 68uC, with a
final extension time of 10 min at 68uC. Amplification of actin
cDNA served as a control. The PCR products were electropho-
resed on a 1.5% agarose gel containing ethidium bromide, and
amplified fragments were visualized under UV transillumination.
Immunohistochemistry
Mice were anesthetized with avertin and perfused transcardially
with 4% paraformaldehyde (PFA). Brains, spinal cords and optic
nerves were dissected in PBS, fixed with 4% PFA overnight at 4uC,
cryoprotected in 30% sucrose overnight at 4uC, then frozen in a
1:1 mixture of 30% sucrose:OCT (Sakura, CA). Cryostat sections
of 10 mm thickness were obtained and stored at 220uC until use.
Sections were postfixed in 70% ethanol for 5 min, rinsed with PBS
for 10 min, and incubated in warm citrate buffer (10 mM citric
acid, 26 mM NaOH, pH 6) for 10 min. Sections were then
blocked using TBLS (0.5 mM Tris-HCl pH 7.4, 0.0085% NaCl,
0.01% BSA, 0.009% L-lysine, and 10% sodium azide) with 20%
goat serum and 0.3% Triton-X-100 for 1 hour. Primary
antibodies for CC-1 (1:10, Abcam, MA), GFAP (1:500, chemicon),
Ng2 (1:250, Millipore), NeuN (1:100, Chemicon), and Cre (1:100,
Novagen) were diluted in TBLS and incubation was for 1 hour at
RT and overnight at 4uC, respectively. Secondary antibodies were
used at a dilution of 1:200 (Invitrogen), and Hoechst counterstain
at 1:10,000. Slides were mounted with a fluorescence mounting
medium (Dako North America, Inc.) and sections analyzed by
fluorescence microscopy using a Zeiss Axioplan microscope or
Zeiss Confocal microscope (LSM 510 Meta DuoScan). Cells were
considered to be Cre positive only if they had a clear nuclear
staining pattern co localizing with DAPI. All images for co labeling
analysis were done using the Zeiss Confocal microscope set at a
1 mm slice capture.
b-galactosidase staining
Heterozygous male Plp-Cre or Plp-CreER
t mice were bred with
female Rosa26
LacZ homozygotes. The Cre positive offspring should
harbor cells expressing a functional Cre-recombinase enzyme;
hence allowing expression of lacZ driven by the ROSA26
promoter. Cre-positive Rosa26
LacZ heterozygous progeny were
analyzed for b-galactosidase enzyme activity, with Cre-negative
Rosa26
LacZ heterozygotes serving as controls. Mice were anesthe-
tized with avertin and perfused transcardially using 0.2%
glutaraldehyde with 1.25 mM EGTA pH 7.3 and 2 mM MgCl2
in PBS. Tissues (brain, spinal cord, sciatic nerve, optic nerve) or
embryos were then postfixed in 0.2% glutaraldehyde solution for 1
to 4 additional hours at 4uC, then rinsed 3 times with PBS. Tissues
were incubated from 2 hours to overnight at 37uC in X-Gal
staining solution consisting of 5 mM potassium ferricyanide,
5 mM potassium ferrocyanide, 2 mM MgCl2, 0.02% Nonidet P-
40, and 1 mg/ml of 5-bromo-4-chloro-3-indolyl-b-D-galactopyr-
anoside (X-Gal) in 0.1 M phosphate buffer, pH 8. Samples were
then washed 3 times with PBS and whole mount photographs
were taken.
Results
Generation of Plp-Cre transgenic mice
To direct oligodendrocyte specific expression, full-length Cre
cDNA was placed under control of the mouse Plp promoter
(Fig. 1A). The promoter region consists of exon 1 and intron 1 of
the Plp gene, shown previously to be sufficient for mimicking the
endogenous Plp activity (7). Six of 29 potential founders tested
positive for the transgene construct with two successfully breeding
and transmitting the transgene to subsequent generations (Fig. 1B).
From these two founders, independent lines 627 and 633,
described herein, were generated.
The Plp-Cre transgenic mice display CNS-specific
expression
Specificity of Plp-Cre expression to CNS tissues in lines 627 and
633 was initially assessed by RT-PCR. To compare early and later
stage transgene expression, total RNA was isolated from selected
tissues at P4 and P28. At P28, both lines exhibited a CNS-specific
expression pattern, with transcripts detected in, for example, spinal
cord, cerebellum and cortex (Fig. 1C). At P4, transgene expression
was also detected in CNS tissues (Fig. 1C). However, at this stage,
mice from line 627 also expressed the Cre transgene in kidney,
PLP Activity outside of Myelinating Cell Lineages
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noted that for the purpose of this study the transgene was
consistently expressed at higher levels in CNS tissues relative to all
other tissues examined.
Plp-Cre transgene expression displays selectivity to
oligodendrocytes in later postnatal stage mice
Immunocytochemistry was performed to assess specificity of
Cre protein expression to oligodendrocytes. Cerebellar, spinal
cord, and optic nerve sections from P4 and P28 Plp-Cre
transgenic mice and their wild type littermates were examined.
An antibody against CC-1 was used as a marker for mature
oligodendrocytes. In both Plp-Cre lines (627 and 633), all neural
tissues examined at P28 expressed the Cre protein. The majority
of Cre-positive cells also labeled positive for CC-1 (see Table 1),
indicating specificity of the Plp promoter to mature oligodendro-
cytes at this stage in postnatal development (spinal cord Fig. 2D–
I, cerebellum Fig. 3D–I, and optic nerve Fig. S1D–I). As
expected, we did not detect any Cre-positive cells in tissues from
WT littermates (Fig. 2A–C, Fig. 3A-C, and Fig. S1A–C). There
were a few faintly labeled Cre-positive cells that also co-labeled
with the astrocytic marker GFAP (Fig. 2J, Fig. 3J and Fig. S1J) as
well as with Ng2, a marker for oligodendrocyte progenitor cells
(OPCs) (Fig. 2K, Fig. 3K and Fig. S1K) (summarized in Table 1).
In comparison, there were no Cre-positive cells that co-labeled
with NeuN, a marker for mature neurons, in the tissues
examined (Figs. 2L and 3L).
At P4, Cre protein was detected in both spinal cord (Fig. 4, Fig.
S2, Fig. S3) and cerebellum (Fig. 5, Fig. S4, Fig. S5) of Plp-Cre
transgenic mice. However, unlike the situation at the P28 stage,
Cre expression was often more widespread, with many Cre-
positive cells outside of the oligodendrocyte lineage, especially in
the cerebellum (see Table 2).
In the spinal cord, the most intensely stained Cre-positive cells
localized predominantly to emerging white matter tracts, and co-
labeled with the oligodendrocyte marker CC-1 (Fig. 4A–B, G–H,
Fig. S2A–C). Approximately a third of Cre-positive cells co-
labeled with Ng2 (Fig. 4C–D, I–J, Fig. S2D–F). However, a
considerable number of Cre-positive cells also were positive for the
astrocyte marker GFAP, both in white and grey matter regions
(Fig. 4E–F, K–L, Fig. S2G–I). As the cumulative percentage of
Cre-positive cells expressing markers for CC-1 and GFAP exceeds
100%, it is suggested that GFAP positive cells are often also
labeled by CC-1 at P4 (these cells would be considered astrocytes)
(see Table 2). There was no co-labeling of Cre-positive cells with
the neuronal marker NeuN at this time point (Fig. S3).
Figure 1. Schematic and expression profile of Plp-Cre transgene. A. Schematic representation of the Plp-Cre transgene construct. The mouse
Plp promoter is used to drive expression of the Cre cDNA. The initiating ATG within exon 1 has been mutated to prevent initiation of translation
within the promoter region. B. Summary of Plp-Cre transgenic mice generated. C. RT-PCR analysis of the tissue expression profile of the Plp-Cre
transgene for both founder lines. At P28, both lines adhered to a strictly CNS-specific expression pattern, with transcripts detected in the spinal cord,
cerebellum and cortex. At P4, the transgene transcript in line F633 was detected solely in CNS tissues, whereas line F627 displayed a more widespread
expression pattern, with transcripts also detected in kidney, liver and TA muscle. SC = spinal cord, Cer = cerebellum, Cor = cortex, Spln = spleen,
Kid = kidney, Liv = liver, TA = tibialis anterior muscle. Actin mRNA amplification was used as control.
doi:10.1371/journal.pone.0019772.g001
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deep central white matter region, the zone of initial myelination.
Approximately half (see Table 2) of the central white matter
regions Cre-positive cells were CC-1 positive (Fig. 5A–B, G–H,
Fig. S4A–C). Cre-positive cells within the region also co-labeled
with Ng2 (Fig. 5C–D, I–J, Fig. S4D–F), and a small number with
GFAP (Fig. S5). Most striking was the Cre staining pattern in the
developing granular, Purkinje and molecular cell layers. Almost no
CC-1 positive cells were identified and less than 10% of Cre-
positive cells within this region co-stained for Ng2 in both
transgenic lines (data not shown). Approximately half (see Table 2)
of all Cre-positive cells co-labeled with NeuN (Fig. 5E–F, K–L,
Fig. S4G–I), suggesting a large population of neurons within the
granular, Purkinje and molecular cell layers in which the PLP
promoter is active at P4.
Inducible model demonstrates PLP promoter expression
outside of oligodendrocytes during early postnatal
development
The above results suggest a temporal shift in the promoter’s
expression pattern. To further validate the observed difference in
Plp promoter activity between early (P4) and late (P28) postnatal
time points, we took advantage of an existing line in which Plp
drives expression of a Cre protein fused to a mutated estrogen
receptor (Plp-CreER
t) [19]. This fusion necessitates activation of
Cre by tamoxifen. The Plp promoter region, similar to our Plp-Cre
transgenic mice, consists of exon 1 and intron 1 of the
endogenous Plp gene, and as such, would be expected to drive
Cre expression in an identical manner. The Plp-CreER
t mice were
crossed to a ROSA26 reporter line (Rosa26
LacZ). Rosa26
LacZ mice
express lacZ driven by the constitutively active ROSA26 locus
promoter [17]. A floxed stop region is located upstream of the
lacZ coding sequence, therefore necessitating Cre-mediated
excision of the stop region to allow for lacZ expression.
Tamoxifen is thus required to induce translocation of CreER
t
from the cytoplasm into the nucleus thereby activating lacZ
expression. For the Plp-CreER
t transgenic line, injections of
tamoxifen were given at P16 and P4. The time points were
chosen to reflect different stages of oligodendrocyte maturation
and the observed temporal shift in Plp promoter patterning
observed in our Plp-Cre mice; that of increasing specificity to the
oligodendrocyte lineage as the animal matures from P4 to P28.
Injections at P4 would allow for early postnatal Plp expression
profiling, while the later P16 time point would reflect the
increasing oligodendrocyte selectivity of the Plp promoter. P16
and P4 tamoxifen injected mice were analyzed at P60 and P28
respectively. Therefore, the reporter-positive cells observed at
P60 and P28 are the progenies of Plp promoter active cells at P16
and P4. The reporter-positive cells at the stages examined do not
necessarily have Plp promoter activity.
The pattern of lacZ expression, as determined by b-galactosidase
activity, in Plp-CreER
t;Rosa26
LacZ mice differed depending on the time
course of tamoxifen administration. In mice given the drug at P16, b-
galactosidase expression was similar to that previously described [19],
localizing mainly to white matter tracts of the CNS (e.g. in the brain,
spinal cord and optic nerve), but not in the PNS (e.g. sciatic nerve)
(Fig. 6A). In contrast, when tamoxifen was given to P4 Plp-
CreER
t;Rosa26
LacZ mice, b-galactosidase was expressed both in CNS
and PNS tissues (Fig. 6B). Also, b-galactosidase expression in P4
brains was not exclusive to CNS white matter tracts; in the
cerebellum b-galactosidase was expressed in the Purkinje cell layer
(PCL) and the internal granular layer (IGL) and was not observed in
the corpus callosum. The b-galactosidase expression profile observed
in the PCL and IGL of P4 injected mice corroborates nicely with our
immunocytochemistry for Cre protein performed at the same time
point (see Fig. 5E–F, K–L). In both P16 and P4 tamoxifen injected
mice, b-galactosidase was expressed in the olfactory bulb, most likely
in olfactory ensheathing cells as reported previously [20].
These experiments suggest Plp promoter driven expression
occurs outside of the oligodendrocyte cell lineage early in postnatal
development, and demonstrates increased oligodendrocyte spec-
ificity as a result of cellular maturation.
Plp-Cre transgene expression during embryonic and
early postnatal development is not restricted to the
myelinating cell lineage
To further assess both the temporal and spatial expression of
Cre from early embryonic stages, we crossed our Plp-Cre transgenic
mice to the Rosa26
LacZ line. Brain, spinal cord, and optic nerve
tissues were examined from two early developmental time points
(E10.5, E15.5). Cells marked by activation of the lacZ reporter
gene would therefore suggest Plp promoter driven Cre expression
either before or at the time of analysis.
b-galactosidase activity was detected in E10.5 whole mount
embryos (Fig. 7A). Robust staining was apparent throughout the
telencephalon, optic stalk, mesencephalon, rhombencephalon, and
spinal cord as well as in PNS derivatives of the neural crest
(Fig. 7A). As the progeny of these cells faithfully inherit the
activated lacZ gene, it was not surprising to observe widespread b-
galactosidase activity in the brains and spinal cords of E15.5
(Fig. 7B) mice. No b-galactosidase expression was observed in
either Plp-Cre or Rosa26
LacZ mice alone (data not shown).
To allow for higher resolution analysis of Plp promoter activity in
CNS tissues at a later time point, Plp-Cre transgenic mice were
crossed to a reporter line expressing tomato red and EGFP driven by
the constitutively active ROSA26 locus (mT/mG). A floxed stop
region located upstream of the EGFP coding sequence necessitates
Cre-mediated excision to allow for EGFP expression. All cells in
which excision of the stop region does not occur would express
tomato red only. Brain and spinal cord sections from P28 Plp-Cre;mT/




%o fC r e +cells
that are CC-1+
a
%o fC r e +cells
that are Ng2+
%o fC r e +cells
that are GFAP+
a
%o fC r e +cells
that are NeuN+
Spinal Cord 88.9%65.4 95.8%66.8 10.8%60.7 10.6%62.2 0
Cerebellum 86.0%64.8 90.0%69.2 5.8%64.3 8.6%65.8 0
Optic Nerve 91.2%66.4 88.7%62.8 3.8%62.5 3.3%60.2 n.d.
aThere are most likely Cre-positive cells which stain for GFAP and CC-1. These cells are assumed to be GFAP astrocytes, and not oligodendrocytes.
n.d.=not determined.
doi:10.1371/journal.pone.0019772.t001
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19772Figure 2. Cre-recombinase is predominantly expressed in oligodendrocytes of P28 Plp-Cre mouse spinal cord. A–I. Ventral white
matter regions were double-stained with antibodies specific to CC-1 as a marker for mature oligodendrocytes (green), Cre (red) and counterstained
with DAPI. Cre was not detected in WT spinal cord sections (B). Sections from transgenic mice of both F633 (D–F) and F627 (G–I) lines exhibited a
similar pattern of Cre expression. High levels of Cre recombinase protein was detected in the CC1-positive oligodendrocytes. J. Ventral white matter
region stained for GFAP (green) as a marker for astrocytes, Cre (red) and counterstained with DAPI. A small number of Cre-positive cells co-labeled
with GFAP (arrow). K. Ventral white matter region stained for Ng2 (green) as a marker for OPCs, Cre (red) and counterstained with DAPI. A small
number of Cre-positive cells co-labeled with Ng2 (arrow). L. Ventral grey matter region stained for NeuN (green) as a neuronal marker, Cre (red) and
counterstained with DAPI. There were no NeuN positive cells that co-labeled with Cre. Scale bar =20 mm.
doi:10.1371/journal.pone.0019772.g002
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19772Figure 3. Cre-recombinase is predominantly expressed in oligodendrocytes of P28 Plp-Cre mouse cerebellum. A–I. Cerebellar sections
were double-stained with antibodies specific to CC-1 as a marker for mature oligodendrocytes (green), Cre (red) and counterstained with DAPI. Cre
was not detected in WT cerebellar sections (B). Sections from transgenic mice of both F633 (D–F) and F627 (G–H) lines exhibited a similar pattern of
Cre expression. High levels of Cre recombinase protein was detected in the CC1-positive oligodendrocytes. J. Cerebellar section stained for GFAP
(green) as a marker for astrocytes, Cre (red) and counterstained with DAPI. A small number of weakly stained Cre-positive cells co-labeled with GFAP
(arrow). K. Representative example within the molecular layer of cerebellar section stained for Ng2 (green) as a marker for OPCs, Cre (red) and
counterstained with DAPI. A small number of weakly stained Cre-positive cells co-labeled with Ng2 (arrow). L. Representative example within
granular layer of cerebellar section stained for NeuN (green) as a neuronal marker, Cre (red) and counterstained with DAPI. There were no NeuN
positive cells co-labeled with Cre. GL = granular layer, WMT = white matter tract. Scale bar =20 mm.
doi:10.1371/journal.pone.0019772.g003
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LacZ
double transgenic line, we observed high levels of EGFP expression
throughout CNS tissues occurring outside of oligodendrocyte-rich
regions (Fig. 8B, C, D). Only very discreet zones remained tomato
red positive, localizing predominantly to macro- and micro-
vasculature in the cerebellum (Fig. 8B), forebrain (Fig. 8C), and
spinal cord (Fig. 8D) areas. A typical example of fluorescent
patterning in the absence of Cre is shown as a control (Fig. 8A).
Both the Rosa26
LacZ and mT/mG reporter lines clearly
demonstrate Plp promoter driven Cre activity outside of the
oligodendrocyte lineage, beginning as early as E10.5. By P28, with
the exception of vasculature, almost all cell types within CNS
tissues examined, either during embryonic and/or early postnatal
development, have activated the Plp promoter region as denoted
by high b-galactosidase or EGFP expression levels.
Discussion
Here we have characterized two independent transgenic mouse
lines in which Cre recombinase is expressed under the control of
the mouse Plp promoter. We demonstrate the Plp promoter
cassette’s capability to drive expression of a Cre recombinase
transgene within the CNS, but in a more widespread pattern than
initially anticipated. This was particularly true at early develop-
mental stages when the transgene was expressed in neural tissues,
and not restricted to the oligodendrocyte lineage, results
corroborated by the work of others [3,14,16,21]. During this
time, transgene expression was also localized to the PNS (sciatic
nerve, ventral and dorsal roots), most likely in Schwann cells. It
was only at late postnatal stages that the Plp-Cre transgene
demonstrated a high level of oligodendrocyte specificity.
At the mRNA level, Cre expression was highly restricted to
CNS tissues (within those examined) at early and late stages of
postnatal development. At both P4 and P28, transgene expression
was detected in cortex, cerebellum, and spinal cord. In addition, at
P4, Cre transcript was also detected in the kidney, liver, skeletal
muscle, and heart of mice from line 627, albeit at a level lower
than that in neural tissues.
At the protein level in the optic nerve, spinal cord, and
cerebellum of P28 transgenic mice Cre recombinase was
Figure 4. Cre-recombinase is expressed both in and outside the oligodendrocyte lineage in spinal cords of P4 Plp-Cre mice. A–L.
Ventral spinal cord sections from WT and Plp-Cre line 627 mice were double-stained with antibodies specific to Cre (red) and either CC-1 (green) as a
marker for mature oligodendrocytes (A–B, G–H), Ng2 (green) as a marker for OPCs (C–D, I–J), or GFAP (green) as a marker for astrocytes (E–F, K–L), and
counterstained with DAPI. Cre was not detected in WT sections (A–F). As expected, many Cre-positive cells were CC-1-positive, however, a large
percentage also co-stained for Ng2 and GFAP. Examples of Cre and glial marker co-labeling are denoted by arrows. WM = white matter, GM = grey
matter. Scale bar = 20 mm.
doi:10.1371/journal.pone.0019772.g004
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staining. However, at P4, Cre protein expression was more
widespread, localizing to granular (Fig. 5E–F, K–L) and Purkinje
cell layers within the cerebellum, and throughout spinal cord
astrocytes. Previous studies have also identified Plp gene products
in the external granular and Purkinje cell layers of the developing
mouse cerebellum, as well as in grey matter astrocytes of the
developing spinal cord [15,22].
Figure 5. Cre-recombinase is expressed both in and outside the oligodendrocyte lineage in the cerebellum of P4 Plp-Cre mice. A–D,
G–J. Deep cerebellar white matter regions from WT and Plp-Cre line 627 mice were double-stained with antibodies specific to Cre (red) and either CC-
1 (green) as a marker for mature oligodendrocytes (A–B, G–H), or Ng2 (green) as a marker for OPCs (C–D, I–J) and counterstained with DAPI. Cre was
not detected in WT sections (A–D). A large percentage of Cre-positive cells within the region co-stained for CC-1 and Ng2. E–F, K–L. Cerebellar
sections of the developing granular layer from WT and Plp-Cre line 627 mice were double-stained with antibodies specific to Cre (red), the neuronal
marker NeuN (green) and counterstained with DAPI. Cre was not detected in WT sections (E–F). Many Cre-positive cells co-stained for NeuN. Examples
of Cre-positive cells co-labeling with neuronal or glial markers are denoted by arrows. Scale bar=20 mm.
doi:10.1371/journal.pone.0019772.g005
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aThere are most likely Cre-positive cells which stain for GFAP and CC-1. These cells are assumed to be GFAP astrocytes, and not oligodendrocytes. This is especially true
for P4 spinal cord.
bCells counted from deep central white matter region of cerebellum.
cCells counted in developing region of cerebellar granular, Purkinje and molecular cell layers.
doi:10.1371/journal.pone.0019772.t002
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19772The fact that the Plp-CreER
t transgenic mice have an inducible
Cre protein allowed for tracking of the Plp promoter activity from
specific developmental stages onwards. Indeed, the administration
of tamoxifen at specific time points allowed us to follow the fate of
cells that were Plp positive at the time of administration. The
reporter-positive cells observed at later stages are the progeny of
Plp promoter active cells at the time of tamoxifen administration.
Mice given tamoxifen at P4 displayed the Plp promoter’s
promiscuity at this early time point, with the result that b-
galactosidase reporter expression was detected in neuronal non-
white matter regions at later time points. In stark contrast, the b-
galactosidase expression profile in mice receiving tamoxifen at P16
was limited strictly to white matter zones at later stages of analysis.
From these studies, a clear Plp promoter driven spatio-temporal
patterning emerges for the CNS – that of neuronal inclusion early
in postnatal development, with later stages defined by increased
oligodendrocyte specificity.
Our transgene product, by analysis of Plp-Cre;Rosa26
LacZ mice,
proved to be functional in a large range of cell types during
embryogenesis. This is dramatically demonstrated in the crosses to
the mT/mG reporter mice, in which, by P28 all but discreet zones
of CNS vasculature expressed excision activated EGFP.
To better understand where and when the Plp promoter is
active in the CNS, it is important to consider the products of the
Plp gene. The promoter drives production of both PLP and its
splice variant DM-20. The splice site is located within exon three
of the gene, producing a transcript product lacking exon 3B [23].
The protein structure of the smaller isoform DM-20 is identical to
PLP except for the removal of amino acids 116 through 150 [24].
DM-20 mRNA has been detected by RT-PCR in the murine
neural tube and spinal cord during embryonic development,
whereas the PLP transcript is the predominant postnatal isoform
[25,26]. In situ hybridization experiments at E10 using a DM-20
anti-sense probe detected signal in both the CNS (neural tube
within the diencephalic basal plate) and the PNS (trigeminal and
spinal ganglia, and sympathetic ganglion chain) [1,25]. Other
studies have confirmed this observation, demonstrating the
presence of PLP/DM-20 RNA transcript as early as E9.5 [2,27].
Figure 7. b-galactosidase expression outside of the oligodendrocyte lineage in CNS tissues of Plp-Cre;ROSA26
LacZ mice at E10.5 and
E15.5. A. b-galactosidase expression in Plp-Cre;ROSA26
LacZ embryos at E10.5. Shown are representative examples of E10.5 embryos from lines F627
and F633 after whole mount X-gal staining. Both lines show b-galactosidase expression throughout the developing brain and spinal cord. B. b-
galactosidase expression in Plp-Cre;ROSA26
LacZ mice at E15.5. Shown is an example of whole mount staining of tissues from line F633. b-galactosidase
activity was detected throughout both the brain, and ventral and dorsal spinal cord. Scale bars=2 mm in A and B Brain and Spinal Cord, 1 mm in A
and B Optic nerve and Sciatic nerve.
doi:10.1371/journal.pone.0019772.g007
Figure 6. b-galactosidase expression in Plp-CreER
t;ROSA26
LacZ mice given tamoxifen at either at P16 or P4. A. b-galactosidase expression
in Plp-CreER
t;ROSA26
LacZ mice given tamoxifen at P16 and examined by whole mount X-gal staining at P60. In the brain, b-galactosidase activity is
predominantly observed in white matter tracts. In the spinal cord, b-galactosidase activity is detected in the dorsal and ventral white matter tracts,
but is absent from the ventral and dorsal roots. Finally, b-galactosidase activity is apparent throughout the length of the optic nerve, but not in the
sciatic nerve. B. b-galactosidase expression in Plp-CreER
t;ROSA26
LacZ mice given tamoxifen at P4 and examined by whole mount X-gal staining at P28.
In the brain, b-galactosidase activity is detectable outside of large white matter tracts. In the spinal cord, b-galactosidase activity is detectable in the
dorsal and ventral white matter tracts, and is also present in the ventral and dorsal roots. Finally, b-galactosidase is expressed throughout the length
of the optic nerve, albeit at a reduced level, and the sciatic nerve is now positive for b-galactosidase activity. CC = corpus callosum, PCL = Purkinje
cell layer, IGL = internal granular layer, VR = ventral root, DR = dorsal root. Scale bars=1 mm in A and B Brain, 500 mm in B Spinal Cord.
doi:10.1371/journal.pone.0019772.g006
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PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19772DM-20 is therefore clearly present in cells long before the
appearance of defined mature or even precursor oligodendrocytes.
Previous studies have shown DM-20 outside of the glial cell
lineage, with expression detected in diverse cell types, including
various neuronal cell lines such as G-26, B104, NG108-15, NG18-
TG, Neuro2A, PC12, and P19 [27,28,29]. PLP/DM-20 tran-
scripts and/or protein have also been found in cells of the thymus,
spleen and testicles [30,31].
Recently, various groups have identified specific cellular
subtypes within the murine CNS expressing Plp gene products at
early embryonic and postnatal stages. One such study tracked the
fate of NG2
+ oligodendrocyte progenitors co-labeling for Plp
promoter driven EGFP [13]. They demonstrated the ability of the
progenitors to not only differentiate into myelinating oligoden-
drocytes, but also into astrocytes and neurons. Another study
compared PLP/DM-20 transcript levels at P5 and adult stages,
Figure 8. EGFP expression occurs outside of the oligodendrocyte lineage in CNS tissue of P28 Plp-Cre;mT/mG mice. A. Representative
example of mT/mG reporter expression in the absence of Cre recombinase in sections of the cerebellum from non-transgenic mice. Only tomato red
expression is detected and EGFP expression is absent. B. EGFP expression in cerebellum of Plp-Cre;mT/mG mice. EGFP is expressed throughout the
cerebellum, including the granular, Purkinje and molecular layers. Non-recombined cells, marked by tomato red expression, are limited to the
vasculature. C. EGFP expression in forebrain region of Plp-Cre;mT/mG mice. EGFP is detected throughout the region. Non-recombined cells, marked
by tomato red expression, are limited predominantly to vasculature. D. EGFP expression in spinal cord of Plp-Cre;mT/mG mice. EGFP is detected
throughout the spinal cord including gray and white matter zones. Non-recombined cells, marked by tomato red expression, are limited to
vasculature. Scale bar=50 mm.
doi:10.1371/journal.pone.0019772.g008
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PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e19772between whole murine cortex and isolated NG2-positive cells. PLP
mRNA was detected in isolated NG2-positive cells at both time
points, whereas DM-20 mRNA was amplified from whole cortex
only [32]. Similar to our own experiments, Delauney and
colleagues crossed Plp-Cre mice to a GFP reporter, subsequently
identifying GFP-positive neuroepithelial cells at E9.5, with the
expressing profile switching to reporter-positive radial glial cells by
E13.5 [3].
Thus, it is clear that the two Plp gene products yield varying and
different expression profiles, and can be generally classified as
follows – Plp, while expressed early in various CNS cellular
subtypes, is at its highest levels postnatally and in an oligoden-
drocyte-specific manner, while DM-20 is preferentially expressed
early and diffusely in the embryo. It is therefore important to
recognize the possibility for Plp promoter driven transgene
expression simply as a by-product through activation of factors
normally involved in DM-20 regulation.
Interestingly, in 1999 a novel exon was discovered lying within
intron 1 of the Plp gene. Termed exon 1.1, it produced a protein
with an additional 12 amino acid leader sequence [33]. The
additional sequence allowed for expression of two further Plp
variants, termed sr-PLP and sr-DM-20. These proteins have been
detected in oligodendrocytes, muscle, and to an even larger extent
in neurons [11,14,33]. Two similar novel exons have recently been
discovered in intron 1 of the human Plp1 gene, giving rise to
unique PLP isoforms [34]. The isoforms are expressed predom-
inantly in neurons and to lesser extent in oligodendrocytes,
beginning during human fetal development. The authors suggest a
role for the proteins in axonal-glial communication, the disruption
of which would account for neuronal dysfunction in humans
carrying Plp1 mutations.
The very early and widespread expression of our transgene
product forces us to reconsider certain aspects of Plp gene
regulation. Perhaps there are regulatory elements activated
differentially for each of the Plp derived isoforms, responsible for
the specific spatial and temporal expression patterns observed
during embryonic and postnatal development. Recent evidence
suggests that this could indeed be the case. Within the Plp gene, six
evolutionary conserved non-protein coding sequences were
identified as Plp/DM-20 enhancers, five of which were located
within intron 1 [16]. When inserted as single copies driving
expression of an EGFPLacZ reporter gene, each unique regulatory
sequence matched characterized components of the Plp promoter’s
spatio-temporal expression profile as seen through a spectra of
glial and neuronal lineage patterning.
The present study informs on Plp promoter functionality as a
driver for both Cre and other transgene expression. Since the goal
of many such studies is oligodendrocyte targeting within the CNS,
it is important to better understand differences in gene regulation
between Plp splice variants. Once more information is obtained
deciphering the different regulatory elements governing expression
of Plp/DM-20 and sr-Plp/sr-DM-20, one could perhaps design a
more specific promoter construct, which would allow for a
postnatal, and more robust oligodendrocyte-specific expression of
the requisite transgene. In the mean time, our work would stress
that as long as one uses the tamoxifen inducible system (Plp-CreER
t)
and induces Cre activity at adult stages, one can achieve
oligodendrocyte specific excision of target genes.
Supporting Information
Figure S1 Cre-recombinase is predominantly expressed
in oligodendrocytes of P28 Plp-Cre mouse optic nerves.
A-I. Optic nerve sections were double-stained with antibodies
specific to CC-1 as a marker for mature oligodendrocytes (green),
Cre (red) and counterstained with DAPI. Cre was not detected in
WT optic nerve sections (B). Sections from transgenic mice of
both F633 (D-F) and F627 (G-I) lines exhibited a similar pattern
of Cre expression. High levels of Cre recombinase protein were
detected in the CC1-positive oligodendrocytes. J. Optic nerve
section stained for GFAP (green) as a marker for astrocytes, Cre
(red) and counterstained with DAPI. A very small number of Cre-
positive cells were also positive for GFAP. K. Optic nerve section
stained for Ng2 (green) as a marker for OPCs, Cre (red) and
counterstained with DAPI. A very small number of weakly
stained Cre-positive cells co-labeled with Ng2 (arrow). Scale
bar=20 mm.
(TIF)
Figure S2 Cre-recombinase is expressed both in and
outside of the oligodendrocyte lineage in the spinal cord
of Plp-Cre mice from line 633. A-I. Ventral spinal cord
sections from Plp-Cre line 633 mice were double-stained with
antibodies specific to Cre (red) recombinase and either CC1
(green) for mature oligodendrocytes (A–C), Ng2 (green) for OPCs
(D–F) or GFAP (green) for astrocytes (G–I) and counterstained
with DAPI. Similar to line 627 many Cre-positive cells were CC-1-
positive, however, a large percentage also co-stained for Ng2 and
GFAP. Examples of Cre and glial marker co-labeling are denoted
by arrows. WM = white matter, GM = grey matter. Scale
bar=20 mm.
(TIF)
Figure S3 Cre-recombinase is not expressed in spinal
cord neurons of P4 Plp-Cre mice. A–I. Ventral spinal cord
sections were double-stained with antibodies specific to NeuN
(green) as a marker for mature neurons, Cre (red), and
counterstained with DAPI. Cre was not detected in WT sections
(B). The low level puncti signal in the alpha motor neurons is
background fluorescence. Sections from transgenic mice of both
633 (D–F) and 627 (G–I) lines exhibited a similar pattern of Cre
expression. Cre-positive cells did not co-label with NeuN. Scale
bar=20 mm.
(TIF)
Figure S4 Cre-recombinase is expressed both in and
outside of the oligodendrocyte lineage in the cerebellum
of Plp-Cre mice from line 633. A–F. Deep cerebellar white
matter regions from Plp-Cre line 633 mice were double-stained
with antibodies specific to Cre (red) and either CC-1 (green) as a
marker for mature oligodendrocytes (A–C), or Ng2 (green) as a
marker for OPCs (D–F) and counterstained with DAPI. Similar to
line 627, a large percentage of Cre-positive cells within the region
co-stained for CC-1 and Ng2. G–I. Cerebellar sections of the
developing granular layer from Plp-Cre line 633 mice were double-
stained with antibodies specific to Cre (red), the neuronal marker
NeuN (green) and counterstained with DAPI. Similar to line 627,
many Cre-positive cells co-stained for NeuN. Examples of Cre-
positive cells co-labeling with neuronal or glial markers are
denoted by arrows. Scale bar=20 mm.
(TIF)
Figure S5 Cre-recombinase is expressed in cerebellar
astrocytes of P4 Plp-Cre mice. A–I. Deep cerebellar white
matter region sections were double-stained with antibodies specific
to GFAP (green) as a marker for astrocytes, Cre (red), and
counterstained with DAPI. Cre was not detected in WT sections
(B). Sections from transgenic mice of both 633 (D–F) and 627 (G–
I) lines exhibited a similar pattern of Cre expression. Only a small
number of Cre-positive cells co-stained with GFAP. Examples of
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